Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30901629 | 0.98 | CYP2A6 (0.50) | CYP2A6ALDH1A1CYP1A2PRKCZCYP11B2 | |
| Ammonia Solution, Strong SCHEMBL28546873 | 0.98 | CYP2A6 (0.50) | CYP2A6ALDH1A1CYP1A2PRKCZCYP11B2 | |
| SCHEMBL24622042 | 0.80 | CYP1A2 (0.42) | CYP2A6ALDH1A1CYP1A2CYP11B2CYP11B1 | |
| SCHEMBL21803768 | 0.79 | HPRT1 (0.50) | CYP2A6ALDH1A1CYP1A2TSHRCYP3A4 | |
| SCHEMBL30464325 | 0.79 | HSD17B10 (0.47) | CYP2A6ALDH1A1CYP1A2PRKCZCYP11B2 | |
| SCHEMBL10094643 | 0.77 | CYP11B2 (0.54) | CYP2A6ALDH1A1CYP1A2PRKCZCYP11B2 | |
| SCHEMBL27329360 | 0.77 | HPRT1 (0.54) | CYP2A6ALDH1A1CYP1A2TSHRCYP3A4 | |
| SCHEMBL10200877 | 0.76 | KDM4E (0.42) | ALDH1A1CYP1A2KDM4ECYP3A4CYP2D6 | |
| SCHEMBL20873066 | 0.75 | PRKCZ (0.64) | CYP1A2PRKCZCYP11B2CYP11B1ADRA2A | |
| SCHEMBL10200876 | 0.74 | KDM4E (0.41) | ALDH1A1CYP1A2ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1647 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818628-B | Preparation method of nitrogen-containing aromatic dicarboxylic acid | 常熟理工学院 | 2020-11-06 | — | — | CN | claimed |
| CN-110818628-A | Preparation method of nitrogen-containing aromatic dicarboxylic acid | 常熟理工学院 | 2020-02-21 | — | — | CN | claimed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | claimed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | claimed |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | claimed |
| CN-101784278-A | Purin derivatives for use in the treatment of FAB-related diseases | BOEHRINGER INGELHEIM INT | 2010-07-21 | — | — | CN | claimed |
| EP-2190434-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2010-06-02 | — | — | EP | claimed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| WO-2009024542-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-26 | — | — | WO | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| WO-2024130411-A1 | PROTEASE INHIBITORS AND METHODS OF USING SAME | VARIATIONAL AI INC. (CA) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024102989-A1 | NON-PEPTIDIC SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024086111-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-114907251-B | Method for constructing methyl heterocyclic compound by palladium-catalyzed alkyne nucleophilic methylation reaction | 大连理工大学 | 2024-03-08 | — | — | CN | disclosed |
| CN-114907251-B | Method for constructing methyl heterocyclic compound by palladium-catalyzed alkyne nucleophilic methylation reaction | 大连理工大学 | 2024-03-08 | — | — | CN | disclosed |
| EP-0175263-B1 | 2-AMINO-3-CHLOROMETHYL-5-(DICHLOROMETHYL)-PYRAZINES AND PROCESS FOR THEIR PREPARATION | BASF Aktiengesellschaft (DE) | 1991-06-05 | — | — | EP | disclosed |
| US-4692527-A | 2-amino-3,5-di-(halomethyl)-pyrazines and their preparation | BASF AKTIENGESELLSCHAFT (DE) | 1987-09-08 | — | — | US | disclosed |
| CN-85102138-A | The preparation method of pyrimidoisoquinolinederivatives derivatives | — | 1986-04-10 | — | — | CN | disclosed |
| EP-0175263-A2 | 2-Amino-3-chloromethyl-5-(dichloromethyl)-pyrazines and process for their preparation | BASF Aktiengesellschaft (DE) | 1986-03-26 | — | — | EP | disclosed |
| US-4053318-A | SENSITIZING MEROCYANINE DYE | FUJI PHOTO FILM CO., LTD. (JA) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, ENTPD5, NUDT14 | CYP2A6 4497/4885ALDH1A1 3607/4885CYP1A2 4770/4885 |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, PURB, NUDT14 | CYP2A6 4146/4885ALDH1A1 3774/4885CYP1A2 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.